• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2023, Vol. 40 ›› Issue (4): 344-348.

• 药品评价 • 上一篇    下一篇

血栓通联合依达拉奉右坎醇治疗急性进展性脑梗死有效性及对神经功能、炎症-氧化应激的改善作用

 许鹏龙1, 管民2, 李刚2   

  1. 1.许昌医院, 河南 许昌 461000;  2.河南省人民医院, 河南 郑州 450000
  • 收稿日期:2023-05-09 修回日期:2023-07-14 出版日期:2023-08-28 发布日期:2023-08-28

Efficacy of Xueshuantong combined with Edaravone Dexcanol in the Treatment of Acute Progressive Cerebral Infarction and the Improvement of Nerve Function,Inflammatory and Oxidative Stress

  1. 1.Xuchang Hospital, Henan Xuchang 461000, China;  2.Henan Provincial People′s Hospital, Henan Zhengzhou 450000, China
  • Received:2023-05-09 Revised:2023-07-14 Online:2023-08-28 Published:2023-08-28

摘要: 目的:探讨血栓通联合依达拉奉右坎醇治疗急性进展性脑梗死(APCI)有效性及对神经功能、炎症-氧化应激的改善作用。方法:选取我院2021年1月至2022年6月收治的APCI患者120例,按照随机数字表法分为参照组和联合用药组,每组各60例。参照组给予依达拉奉右坎醇,联合组在此基础上给予血栓通。比较2组疗效、神经功能损伤(NIHSS评分)、神经损伤因子[细胞间黏附因子-1(ICAM-1)、胶质纤维酸性蛋白(GFAP)、β-肌动蛋白(β-actin)]、简明精神状态检查量表(MMSE)、炎症-氧化应激[白细胞介素-1β(IL-1β)、基质金属蛋白酶-9(MMP-9)、超氧化物歧化酶(SOD)、髓过氧化物酶(MPO)]、日常生活能力(BI指数)及不良反应。结果:联合组总有效率88.33%高于参照组73.33%(P<0.05);治疗2周后,联合组NIHSS、MMSE、BI评分改善幅度大于参照组(P<0.05);联合组ICAM-1、GFAP、β-actin均低于参照组(P<0.05);联合组血清IL-1β、MMP-9、MPO水平明显低于参照组,SOD水平高于参照组(P<0.05);组间不良反应发生率比较,无显著性差异(P>0.05)。结论:血栓通联合依达拉奉右坎醇能有减轻APCI患者神经损伤,抑制炎症-氧化应激,促进神经功能、认知功能改善,提高患者日常生活能力。

关键词: font-size:medium, ">血栓通;依达拉奉右坎醇;脑梗死;神经功能

Abstract: Objective: To investigate the efficacy of Xueshuantong combined with Edaravone dexcanol in the treatment of acute progressive cerebral infarction (APCI) and the improvement of nerve function, inflammatory and oxidative stress. Methods: One hundred and twenty patients with APCI admitted to our hospital from January 2021 to June 2022 were selected and divided into 60 cases each according to random number table method. The reference group was given edaravone dexcanol, and the combination group was given Xueshuantong on this basis. The therapeutic effect, nerve function impairment (NIHSS score), nerve injury factors (ICAM-1), glial fibrillary acidic protein (GFAP), β-actin (β-Actin), brief Mental state Examination Scale (MMSE), inflammatory and oxidative stress (interleukin-1β (IL-1β) were compared between 2 groups, matrix metalloproteinase-9 (MMP-9), superoxide dismutase (SOD), myeloperoxidase (MPO)], daily living ability (BI index) and adverse reactions. Results: The total effective rate of the combined group was 88.33% higher than that of the reference group (P<0.05). After 2 weeks of treatment, the improvement of NIHSS, MMSE and BI scores in combination group was greater than that in reference group (P<0.05). ICAM-1, GFAP and β-actin in combination group were lower than those in reference group (P<0.05). The levels of IL-1β, MMP-9 and MPO in combination group were significantly lower than those in reference group, and the level of SOD was higher than that in reference group (P<0.05). There was no significant difference in the incidence of adverse reactions between groups (P>0.05). Conclusion: Xueshuantong combined with Edaravone dexcanol can alleviate nerve injury, inhibit inflammatory and oxidative stress, promote the improvement of nerve function and cognitive function, and improve the ability of daily living in patients with APCI, and has a good effect.

Key words: font-size:medium, "> , Xueshuantong; Edaravone dexcanol; Cerebral infarction; Neural function

中图分类号: